<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04261660</url>
  </required_header>
  <id_info>
    <org_study_id>CMC-19-0161-CTIL</org_study_id>
    <nct_id>NCT04261660</nct_id>
  </id_info>
  <brief_title>Vascular Endothelial Growth Factor Levels in Patients Undergoing Embryo Transfer</brief_title>
  <official_title>Vascular Endothelial Growth Factor Levels in Patients Undergoing Embryo Transfer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Carmel Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Carmel Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Assessing the relationship between the VEGF levels in blood and the IVF protocol
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The investigators are assessing the VEGF levels in the blood in IVF patients undergoing
      different protocols
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">March 1, 2020</start_date>
  <completion_date type="Anticipated">April 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">March 1, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>vascular endothelial growth factor LEVELS</measure>
    <time_frame>5 days</time_frame>
    <description>levels of vascular endothelial growth factor in blood</description>
  </primary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Reproductive Techniques</condition>
  <arm_group>
    <arm_group_label>fresh</arm_group_label>
    <description>NO INTERVENTION</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Frozen embro transfer natural</arm_group_label>
    <description>NO INTERVENTION</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Frozen embro transfer hormonal</arm_group_label>
    <description>NO INTERVENTION</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>NO intervention</intervention_name>
    <description>NO INTERVENTION</description>
    <arm_group_label>Frozen embro transfer hormonal</arm_group_label>
    <arm_group_label>Frozen embro transfer natural</arm_group_label>
    <arm_group_label>fresh</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Patients serum
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Female patients undergoing ovum pickup and embryo transfer as part of assited reproductive
        technologies
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Patients undergoing IVF -

        Exclusion Criteria:

          -  Women with any malignancy

          -  Patients request to be withdrawn
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>PATIENTS UNDERGOING IN VITRO FERTLIZATION</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Ido Feferkorn, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Carmel Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>ido Fefekorn, MD</last_name>
    <phone>+972-54-3537401</phone>
    <email>idofe@clalit.org.il</email>
  </overall_contact>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>February 6, 2020</study_first_submitted>
  <study_first_submitted_qc>February 7, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 10, 2020</study_first_posted>
  <last_update_submitted>February 7, 2020</last_update_submitted>
  <last_update_submitted_qc>February 7, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 10, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Carmel Medical Center</investigator_affiliation>
    <investigator_full_name>Ido Feferkorn</investigator_full_name>
    <investigator_title>Physician</investigator_title>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

